Using a state-of-the-art rigorous proteomic approach and validation in a completely independent cohort, we identified and positively validated six promising CSF biomarker candidates for DLB, namely VGF, SCG2, NPTX2, NPTXR, PDYN and PCSK1N (proSAAS). The gene discussed is PCSK1N; the disease is Lewy body dementia.